1. Home
  2. LZM vs EDIT Comparison

LZM vs EDIT Comparison

Compare LZM & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifezone Metals Limited

LZM

Lifezone Metals Limited

HOLD

Current Price

$3.75

Market Cap

391.3M

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.54

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LZM
EDIT
Founded
2021
2013
Country
Isle of Man
United States
Employees
93
N/A
Industry
Metal Mining
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
391.3M
432.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
LZM
EDIT
Price
$3.75
$3.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$7.00
$5.30
AVG Volume (30 Days)
741.0K
2.6M
Earning Date
03-19-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$86.37
N/A
Revenue Next Year
$202.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$3.07
$1.66
52 Week High
$6.40
$4.54

Technical Indicators

Market Signals
Indicator
LZM
EDIT
Relative Strength Index (RSI) 43.08 69.20
Support Level $3.62 $3.32
Resistance Level $4.32 $3.65
Average True Range (ATR) 0.32 0.23
MACD -0.02 0.10
Stochastic Oscillator 22.32 97.30

Price Performance

Historical Comparison
LZM
EDIT

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: